Pharmacokinetics and Safety Study of Rifamycin SV-MMX® 600 mg Tablets After Single and Multiple t.i.d. Doses in Healthy Male and Female Volunteers

NCT02969252 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2018-01-26

No results posted yet for this study

Summary
Conditions
Interventions
Sponsors
Investigators
Design
Eligibility
Timeline
Countries
Locations
Related
Entities

Summary

The objective of the study was to evaluate the pharmacokinetics and the safety of rifamycin SV after single and multiple doses of Rifamycin SV-MMX® 600 mg tablets administered to male and female healthy subjects.

Conditions

Healthy

Interventions

DRUG: Rifamycin SV-MMX® 600

Sponsors & Collaborators

Cosmo Technologies Ltd
lead INDUSTRY

Study Design

Allocation: NA
Purpose: OTHER
Masking: NONE
Model: SINGLE_GROUP

Eligibility

Min Age: 18 Years
Max Age: 55 Years
Sex: ALL
Healthy Volunteers: Yes

Timeline & Regulatory

Start: 2015-07-31
Primary Completion: 2015-08-31

Summary

Conditions

Interventions

Sponsors & Collaborators

Study Design

Eligibility

Timeline & Regulatory

Related Clinical Trials

A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers

Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects

A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects

Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant

Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients

More Related Trials